ZBH$90.335
Chart
Performance
Key Stats
AI ZBH Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyZimmer Biomet demonstrates solid fundamental strength in the medical technology sector, with consistent profitability and a manageable debt level. While recent performance shows some variability, the company's position in orthopedic and reconstructive products offers long-term growth potential. Technical indicators suggest a recent downtrend, but a potential for stabilization exists.
Thematic
Zimmer Biomet operates within the stable but evolving medical technology and healthcare sector. Key themes include an aging global population driving demand for orthopedic solutions, advancements in minimally invasive surgery, and the integration of digital health technologies. While these themes are generally positive, competition and regulatory changes are significant factors.
Fundamental
Zimmer Biomet demonstrates strong financial health with consistent revenue generation, healthy gross margins, and a manageable debt-to-equity ratio. Profitability has shown resilience, though some quarters reflect market pressures. The company maintains a solid cash flow position, supporting its operations and dividend payouts.
Technical
The stock price of Zimmer Biomet has experienced a recent decline, with technical indicators suggesting downward momentum. While trading below key moving averages, some oscillators show oversold conditions, hinting at a potential for a short-term bounce. Key support levels need to hold to prevent further downside.
| Factor | Score |
|---|---|
| Aging Global Population | 85 |
| Technological Advancements | 75 |
| Healthcare Policy & Regulation | 50 |
| Competition | 65 |
| Emerging Market Penetration | 75 |
| Factor | Score |
|---|---|
| Valuation | 65 |
| Profitability | 80 |
| Growth | 70 |
| Balance Sheet Health | 85 |
| Cash Flow | 88 |
| Dividend Yield | 75 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 50 |
| Volume Confirmation | 60 |
| Support & Resistance | 70 |
| Fibonacci Retracement | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Attractive Valuation Multiples
The trailing P/E ratio of 28.6 is lower than the industry average, and the Price/Sales ratio of 3.3 is also competitive, suggesting potential undervaluation relative to peers.
Consistent EPS Beat
Zimmer Biomet has a history of beating earnings estimates, with 8 out of the last 12 quarters showing positive EPS surprises, indicating reliable profitability.
Bearish Points (7)
Elevated P/E Ratio
The current P/E ratio of 28.6 is higher than its 2022 level (82.8), but the P/E for 2025 Q1 is significantly higher at 122.7, potentially indicating future earnings are being priced in aggressively.
Short-Term Downtrend Indicators
Multiple moving averages (10, 20, 30, 50, 100, 200 day EMAs and SMAs) show a 'Sell' signal on the 1m, 5m, and 15m charts, suggesting short-term bearish pressure.
Calendar
June 2025
26
Ex-Dividend Date
July 2025
31
Next Dividend Date
August 2025
7
Next Earnings Date
H: $2.07
A: $1.98
L: $1.79
H: 2.09B
A: 2.06B
L: 1.99B
Profile
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Seasonals
Price Target
108.44 USD
The 39 analysts offering 1 year price forecasts for ZBH have a max estimate of 135.00 and a min estimate of 91.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct and major competitor in orthopedics (joint replacement, trauma, spine) and surgical technologies, including robotics.
Weight: 90
Through its DePuy Synthes segment, J&J is a primary direct competitor in orthopedic implants, trauma, and spine products.
Weight: 88
Direct competitor with significant market share in orthopedic reconstruction, sports medicine, trauma, and wound management.
Weight: 85
Major diversified medical technology company with substantial segments in spine, orthopedics, surgical technologies, and neurovascular products.